Avantis International Equity ETF (AVDE) Stock
Key stats
- Market cap
- $1.53B
- Volume
- Loading
- 52-week high
- $94.82
- 52-week low
- $77.20
Source: third-party data provider, as of November 13, 2026
Recent news

Novo Nordisk Holds Its 2026 Outlook As FDA Review Of Its Blood Disorder Drug Runs Long
Novo Nordisk Holds Its 2026 Outlook As FDA Review Of Its Blood Disorder Drug Runs Long
AVDE

NVO Stock On Track For Worst Week In Over 6 Months After Strategy Day — Direct US Listing Talks, Drug Approval Fail To Halt Slip
NVO Stock On Track For Worst Week In Over 6 Months After Strategy Day — Direct US Listing Talks, Drug Approval Fail To Halt Slip
AVDE

NVO Stock Jumps 4% As European Committee Backs Novo’s Haemophilia Pen
NVO Stock Jumps 4% As European Committee Backs Novo’s Haemophilia Pen
AVDE

AZN Stock Slips After-Hours Following Latest Late-Stage Oncology Trial Miss — Executive ‘Disappointed,’ Reiterates Breast Cancer Focus
AZN Stock Slips After-Hours Following Latest Late-Stage Oncology Trial Miss — Executive ‘Disappointed,’ Reiterates Breast Cancer Focus
AVDE
Technical indicators
- RSI 14
- 50.71
- MACD 12/26/9
- -0.27
- EMA 9 of MACD
- -0.40
- MACD histogram
- 0.13
- SMA 50
- $90.68
- Price below SMA 50
- EMA 50
- $90.32
- Price below EMA 50
- SMA 200
- $89.92
- Price above SMA 200
- EMA 200
- $88.88
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
No analyst data available
Financials
Performance
No data available
Debt & Balance Sheet
No data available
Revenue to Profit
No data available
Earnings
No data available
Source: third-party data provider
Latest news

Novo Nordisk Holds Its 2026 Outlook As FDA Review Of Its Blood Disorder Drug Runs Long
Novo Nordisk Holds Its 2026 Outlook As FDA Review Of Its Blood Disorder Drug Runs Long
AVDE

NVO Stock On Track For Worst Week In Over 6 Months After Strategy Day — Direct US Listing Talks, Drug Approval Fail To Halt Slip
NVO Stock On Track For Worst Week In Over 6 Months After Strategy Day — Direct US Listing Talks, Drug Approval Fail To Halt Slip
AVDE

NVO Stock Jumps 4% As European Committee Backs Novo’s Haemophilia Pen
NVO Stock Jumps 4% As European Committee Backs Novo’s Haemophilia Pen
AVDE

AZN Stock Slips After-Hours Following Latest Late-Stage Oncology Trial Miss — Executive ‘Disappointed,’ Reiterates Breast Cancer Focus
AZN Stock Slips After-Hours Following Latest Late-Stage Oncology Trial Miss — Executive ‘Disappointed,’ Reiterates Breast Cancer Focus
AVDE

Want to Tap Global Growth? These Equity ETFs Could Benefit
Want to Tap Global Growth? These Equity ETFs Could Benefit
AVDE

NVO Stock Drops 6% Despite Raised Guidance As Investors Worry About Injectable GLP-1 Sales Future
NVO Stock Drops 6% Despite Raised Guidance As Investors Worry About Injectable GLP-1 Sales Future
AVDE

NVO Stock Ends Three-Month Winning Streak As Novo Nordisk’s Key Heart Drug Flops, Competition Goes To Court
NVO Stock Ends Three-Month Winning Streak As Novo Nordisk’s Key Heart Drug Flops, Competition Goes To Court
AVDE

Global ETFs to Diversify as Tech Weakness Weighs on Markets
Global ETFs to Diversify as Tech Weakness Weighs on Markets
AVDE

NVO Stock Jumps 3% As EU Approves Oral Wegovy Pill — Retail Notes LLY Is ‘Clearly Behind’ Its Danish Counterpart
NVO Stock Jumps 3% As EU Approves Oral Wegovy Pill — Retail Notes LLY Is ‘Clearly Behind’ Its Danish Counterpart
AVDE

AVDE's 23.6% Annual Gain Shows International Dividends are Outpacing U.S. Markets
AVDE's 23.6% Annual Gain Shows International Dividends are Outpacing U.S. Markets
AVDE
News tone: automated (AI) classification of the article's content, not a price prediction.
About Avantis International Equity ETF
Avantis International Equity ETF invests in a broad set of companies of all market capitalizations across non-U.S. developed countries and is designed to increase expected returns by overweighting securities we believe to be trading at lower valuations with higher profitability ratios. The fund pursues the benefits associated with indexing (diversification, low turnover, transparency of exposures), but with the ability to add value by making investment decisions using information in current prices.
Fundamentals
Trading
Dividend
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 50.71
- MACD 12/26/9
- -0.27
- EMA 9 of MACD
- -0.40
- MACD histogram
- 0.13
- SMA 50
- $90.68
- Price below SMA 50
- EMA 50
- $90.32
- Price below EMA 50
- SMA 200
- $89.92
- Price above SMA 200
- EMA 200
- $88.88
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
No analyst data available
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -5.7 | +3.8 | ||||||||||
| 2022 | -3.5 | -3.5 | +2.6 | -7.3 | +2.5 | -11.2 | +4.7 | -5.3 | -8.5 | +3.6 | +11.3 | -3.2 |
| 2023 | +8.4 | -3.7 | +0.7 | +1.6 | -4.6 | +1.4 | +3.6 | -2.4 | -3.4 | -1.8 | +7.1 | +3.1 |
| 2024 | -0.1 | +1.6 | +3.0 | -2.5 | +5.5 | -4.5 | +3.3 | +5.5 | +3.2 | -4.3 | +0.4 | -4.3 |
| 2025 | +4.2 | +3.9 | +0.2 | +3.9 | +6.2 | +0.3 | -0.8 | +4.9 | +3.5 | +0.2 | +1.9 | +2.2 |
| 2026 | +4.5 | +5.7 | -6.5 | +4.1 | +2.6 | -2.0 | +2.5 | +2.3 | -2.9 | -0.3 | +0.6 |
Corporate actions
Upcoming
No upcoming corporate actions for AVDE




